文献速递腹部技术与安全US

CEUS LI-RADS与血清肿瘤标志物对混合型肝细胞-胆管癌的诊断价值

Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma.
PubMed 文献 · Eur J Radiol · 2022-06-18

回顾性分析66个经病理证实的混合型肝细胞-胆管癌结节的CEUS表现,并按2017版CEUS LI-RADS分类。64个(97.0%)被CEUS识别为恶性,39/53(73.6%)归为LR-M,12个(22.6%)归为LR-5,2个(3.8%)归为LR-4;读者间一致性Kappa为0.60。作者认为CEUS LI-RADS和血清肿瘤标志物有助于减少CHC误诊。

要点

  • CHC在CEUS上缺乏特异性表现,多数(39/53,73.6%)按CEUS LI-RADS归为LR-M。
  • 12/53(22.6%)CHC被归为LR-5,2/53(3.8%)归为LR-4,提示存在误判为HCC的风险。
  • 66个CHC结节中64个(97.0%)被CEUS识别为恶性病变。

核心结论

  • 尽管CHC缺乏特异性CEUS特征,CEUS LI-RADS和血清肿瘤标志物可能有助于减少CHC的误诊;由于CHC涉及的CEUS特征相对复杂,初学者放射科医生有必要学习更多CEUS特征。

研究设计与样本

  • 回顾性分析66个经病理证实的CHC结节,总结CEUS表现,分析血清肿瘤标志物与强化模式的关系,按CEUS LI-RADS标准分类,并用Kappa检验评估放射科医生间对CEUS LI-RADS分类的一致性。

关键影像表现/征象

  • 64/66(97.0%)CHC结节被CEUS识别为恶性病变。
  • 13/66(19.7%)CHC结节表现为肝细胞癌样强化模式,21/66(31.8%)表现为胆管癌样强化模式。
  • 52/62(83.9%)患者AFP升高,19/61(31.1%)CA199升高,13/61(21.3%)AFP和CA199均升高。

诊断标准与关键数值

  • 按CEUS LI-RADS分类:39/53(73.6%)CHC结节归为LR-M,12/53(22.6%)归为LR-5,2/53(3.8%)归为LR-4。
  • 放射科医生间对CEUS LI-RADS分类的读者间一致性Kappa值为0.60。

临床应用与阅片要点

  • 阅片时应注意CHC可表现为肝细胞癌样或胆管癌样强化模式,多数归为LR-M,但部分可归为LR-5或LR-4。
  • 血清AFP和CA199升高可辅助提示CHC,但原文未给出联合诊断的敏感度或特异度。
  • 作者认为初学者放射科医生有必要学习更多CEUS特征以识别CHC的复杂表现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To analyze the contrast-enhanced ultrasound (CEUS) manifestations of combined hepatocellular-cholangiocarcinoma (CHC) and to investigate the diagnostic value of the 2017 version of the CEUS Liver Imaging Reporting and Data System (LI-RADS) and serum tumor markers in CHC.

METHODS: A total of 66 pathologically confirmed CHC nodules were retrospectively analyzed. We summarized the CEUS manifestations of CHC and analyzed the relationship between serum tumor markers and the enhancement pattern of CHC. We also classified CHC according to CEUS LI-RADS criteria. The Kappa test was used to assess the interreader agreement of CEUS LI-RADS between radiologists.

RESULT: According to the results, 52 of 62 (83.9%) patients had elevated alpha-fetoprotein (AFP), 19 of 61 (31.1%) had elevated carbohydrate antigen 199 (CA 199), and 13 of 61 (21.3%) had both elevated AFP and CA 199. Of the 66 CHC nodules, 64 (97.0%) were identified as malignant lesions by CEUS, 13 (19.7%) showed a hepatocellular carcinoma-like enhancement pattern, and 21 (31.8%) showed a cholangiocarcinoma-like enhancement pattern. For the CEUS LI-RADS categories, 39 of 53 (73.6%) CHC nodules were classified as LR-M, 12 (22.6%) were classified as LR-5, and 2 (3.8%) were classified as LR-4. The interreader agreement for the LI-RADS categories was 0.60.

CONCLUSIONS: Although CHC lacks specific CEUS features, CEUS LI-RADS and serum tumor markers can be useful tools for reducing the misdiagnosis of CHC. In addition, due to the relative complexity of the CEUS features involved in CHC, it is necessary for beginning radiologists to learn more about CEUS features.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Wen, Lin, Wu, et al. Diagnostic value of CEUS LI-RADS and serum tumor markers for combined hepatocellular-cholangiocarcinoma. Eur J Radiol. 2022. PMID: 35738166. doi:10.1016/j.ejrad.2022.110415

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。